An elevated PSA, which normalizes, does not exclude the presence of prostate cancer.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 349, doi. 10.1038/sj.pcan.4500819
- By:
- Publication type:
- Article
Works matching IS 13657852 AND DT 2005 AND VI 8 AND IP 4
Results: 16
1
2
Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 375, doi. 10.1038/sj.pcan.4500820
- By:
- Publication type:
- Article
3
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 364, doi. 10.1038/sj.pcan.4500821
- By:
- Publication type:
- Article
4
Impact of diet on prostate cancer: a review.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 304, doi. 10.1038/sj.pcan.4500825
- By:
- Publication type:
- Article
5
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 327, doi. 10.1038/sj.pcan.4500823
- By:
- Publication type:
- Article
6
Expectant management: an option for localized prostate cancer.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 311, doi. 10.1038/sj.pcan.4500824
- By:
- Publication type:
- Article
7
British Prostate Group Spring Meeting 11<sup>th</sup> March 2004.
- Published in:
- 2005
- Publication type:
- Abstract
8
p21<sup>WAF1/CIP1</sup> gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 321, doi. 10.1038/sj.pcan.4500822
- By:
- Publication type:
- Article
9
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 369, doi. 10.1038/sj.pcan.4500827
- By:
- Publication type:
- Article
10
Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 335, doi. 10.1038/sj.pcan.4500826
- By:
- Publication type:
- Article
11
Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 353, doi. 10.1038/sj.pcan.4500831
- By:
- Publication type:
- Article
12
Extracellular matrix degrading enzymes at the prostasome surface.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 344, doi. 10.1038/sj.pcan.4500828
- By:
- Publication type:
- Article
13
Report from London.
- Published in:
- 2005
- By:
- Publication type:
- Editorial
14
Prostate News.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 300, doi. 10.1038/sj.pcan.4500851
- Publication type:
- Article
15
Hypertriglyceridemia as a possible risk factor for prostate cancer.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 316, doi. 10.1038/sj.pcan.4500834
- By:
- Publication type:
- Article
16
Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2005, v. 8, n. 4, p. 359, doi. 10.1038/sj.pcan.4500835
- By:
- Publication type:
- Article